- Home
- UONE vs EQ Comparison
UONE vs EQ Comparison
Compare UONE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UONE
- EQ
- Stock Information
- Founded
- UONE 1980
- EQ 2017
- Country
- UONE United States
- EQ United States
- Employees
- UONE N/A
- EQ N/A
- Industry
- UONE Broadcasting
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- UONE Consumer Discretionary
- EQ Health Care
- Exchange
- UONE Nasdaq
- EQ Nasdaq
- Market Cap
- UONE 74.0M
- EQ 67.9M
- IPO Year
- UONE N/A
- EQ 2018
- Fundamental
- Price
- UONE $1.58
- EQ $1.74
- Analyst Decision
- UONE
- EQ Buy
- Analyst Count
- UONE 0
- EQ 3
- Target Price
- UONE N/A
- EQ $3.00
- AVG Volume (30 Days)
- UONE 11.0K
- EQ 16.3M
- Earning Date
- UONE 08-13-2025
- EQ 08-14-2025
- Dividend Yield
- UONE N/A
- EQ N/A
- EPS Growth
- UONE N/A
- EQ N/A
- EPS
- UONE N/A
- EQ N/A
- Revenue
- UONE $411,386,000.00
- EQ $16,553,000.00
- Revenue This Year
- UONE N/A
- EQ N/A
- Revenue Next Year
- UONE N/A
- EQ N/A
- P/E Ratio
- UONE N/A
- EQ N/A
- Revenue Growth
- UONE N/A
- EQ N/A
- 52 Week Low
- UONE $1.23
- EQ $0.27
- 52 Week High
- UONE $2.23
- EQ $2.26
- Technical
- Relative Strength Index (RSI)
- UONE 43.35
- EQ 70.85
- Support Level
- UONE $1.55
- EQ $1.70
- Resistance Level
- UONE $1.70
- EQ $2.23
- Average True Range (ATR)
- UONE 0.08
- EQ 0.32
- MACD
- UONE -0.00
- EQ 0.06
- Stochastic Oscillator
- UONE 13.64
- EQ 64.86
About UONE Urban One Inc.
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.